Vasopharm Biotech GmbH
Records under this name other than patents Vasopharm Biotech GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Vasopharm Biotech GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,016,431 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,493,075 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,925,877 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 12,458,644 | Process for Preparing Solutions Comprising Biopterin Derivatives Formerly held In force · High confidence | In force | High confidence | |
| US 9,895,372 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 11,717,522 | Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 8,222,238 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Formerly held Term ended Term ended Apr 22, 2024 · USPTO record | Term ended | Term ended Apr 22, 2024 | USPTO record |
| US 7,541,360 | 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level Formerly held Term ended Term ended Dec 30, 2023 · USPTO record | Term ended | Term ended Dec 30, 2023 | USPTO record |
| US 9,382,252 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Formerly held Term ended Term ended Oct 8, 2023 · USPTO record | Term ended | Term ended Oct 8, 2023 | USPTO record |
| US 9,422,289 | Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Formerly held Term ended Term ended Oct 8, 2023 · USPTO record | Term ended | Term ended Oct 8, 2023 | USPTO record |